Alveo Closes $38M in Series A Financing

Alveo Technologies, Inc., a San Francisco, CA-based maker of affordable and accessible infectious disease diagnostic devices, closed a $38m Series A financing.

The round was led by Maxim Merchant Capital, a division of Maxim Group LLC, and included existing and new investors.

The company intends to use the funds to advance the optimization and commercialization of its rapid diagnostic platform for infectious diseases.

Led by Ron Chiarello PhD, Founder and Chief Executive Officer, Alveo is a pre-clinical stage medical diagnostics company that is creating a new ecosystem for the detection of diseases.



Join the discussion